Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects.

Ziauddeen H, Nathan PJ, Dodds C, Maltby K, Miller SR, Waterworth D, Song K, Warren L, Hosking L, Zucchetto M, Bush M, Johnson LV, Sarai B, Mogg K, Bradley BP, Richards DB, Fletcher PC, Bullmore ET.

J Clin Pharmacol. 2013 Oct;53(10):1078-90. doi: 10.1002/jcph.110. Epub 2013 Aug 11.

2.

Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498.

Nathan PJ, Bush MA, Tao WX, Koch A, Davies KM, Maltby K, O'Neill BV, Napolitano A, Skeggs AL, Brooke AC, Richards DB, Williams PM, Bullmore ET.

J Clin Pharmacol. 2012 Oct;52(10):1456-67. Epub 2011 Dec 12.

PMID:
22162534
3.

Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.

Ziauddeen H, Chamberlain SR, Nathan PJ, Koch A, Maltby K, Bush M, Tao WX, Napolitano A, Skeggs AL, Brooke AC, Cheke L, Clayton NS, Sadaf Farooqi I, O'Rahilly S, Waterworth D, Song K, Hosking L, Richards DB, Fletcher PC, Bullmore ET.

Mol Psychiatry. 2013 Dec;18(12):1287-93. doi: 10.1038/mp.2012.154. Epub 2012 Nov 13. Erratum in: Mol Psychiatry. 2014 Dec;19(12):1341.

4.

Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.

Ziauddeen H, Nestor LJ, Subramaniam N, Dodds C, Nathan PJ, Miller SR, Sarai BK, Maltby K, Fernando D, Warren L, Hosking LK, Waterworth D, Korzeniowska A, Win B, Richards DB, Vasist Johnson L, Fletcher PC, Bullmore ET.

Neuropsychopharmacology. 2016 Oct;41(11):2647-57. doi: 10.1038/npp.2016.60. Epub 2016 Apr 25.

5.

Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist.

Nathan PJ, O'Neill BV, Bush MA, Koch A, Tao WX, Maltby K, Napolitano A, Brooke AC, Skeggs AL, Herman CS, Larkin AL, Ignar DM, Richards DB, Williams PM, Bullmore ET.

J Clin Pharmacol. 2012 Apr;52(4):464-74. doi: 10.1177/0091270011399577. Epub 2011 May 24.

PMID:
21610207
6.

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.

Ripley TL, Sanchez-Roige S, Bullmore ET, Mugnaini M, Maltby K, Miller SR, Wille DR, Nathan P, Stephens DN.

Psychopharmacology (Berl). 2015 Sep;232(18):3431-41. doi: 10.1007/s00213-015-3995-x. Epub 2015 Jul 5.

7.

Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.

Chamberlain SR, Mogg K, Bradley BP, Koch A, Dodds CM, Tao WX, Maltby K, Sarai B, Napolitano A, Richards DB, Bullmore ET, Nathan PJ.

Psychopharmacology (Berl). 2012 Dec;224(4):501-9. doi: 10.1007/s00213-012-2778-x. Epub 2012 Jul 3.

PMID:
22752384
8.

The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking.

Giuliano C, Goodlett CR, Economidou D, García-Pardo MP, Belin D, Robbins TW, Bullmore ET, Everitt BJ.

Neuropsychopharmacology. 2015 Dec;40(13):2981-92. doi: 10.1038/npp.2015.152. Epub 2015 Jun 5.

9.

Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist.

Ignar DM, Goetz AS, Noble KN, Carballo LH, Stroup AE, Fisher JC, Boucheron JA, Brainard TA, Larkin AL, Epperly AH, Shearer TW, Sorensen SD, Speake JD, Hommel JD.

J Pharmacol Exp Ther. 2011 Oct;339(1):24-34. doi: 10.1124/jpet.111.180943. Epub 2011 Jun 28.

10.

Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people.

Cambridge VC, Ziauddeen H, Nathan PJ, Subramaniam N, Dodds C, Chamberlain SR, Koch A, Maltby K, Skeggs AL, Napolitano A, Farooqi IS, Bullmore ET, Fletcher PC.

Biol Psychiatry. 2013 May 1;73(9):887-94. doi: 10.1016/j.biopsych.2012.10.022. Epub 2012 Dec 14.

11.

Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.

Giuliano C, Robbins TW, Nathan PJ, Bullmore ET, Everitt BJ.

Neuropsychopharmacology. 2012 Nov;37(12):2643-52. doi: 10.1038/npp.2012.128. Epub 2012 Jul 18.

12.

Attenuation of cocaine and heroin seeking by μ-opioid receptor antagonism.

Giuliano C, Robbins TW, Wille DR, Bullmore ET, Everitt BJ.

Psychopharmacology (Berl). 2013 May;227(1):137-47. doi: 10.1007/s00213-012-2949-9. Epub 2013 Jan 9.

13.

Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.

Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, Newbould RD, Howard J, Miller SR, Bush MA, Hill S, Reiley R, Passchier J, Gunn RN, Matthews PM, Bullmore ET.

Mol Psychiatry. 2011 Aug;16(8):826-35, 785. doi: 10.1038/mp.2011.29. Epub 2011 Apr 19.

14.

Evaluation of the safety, pharmacodynamic, and pharmacokinetic effects following oral coadministration of immediate-release morphine with ethanol in healthy male participants.

Setnik B, Sokolowska M, Johnson F, Oldenhof J, Romach M.

Hum Psychopharmacol. 2014 May;29(3):251-65. doi: 10.1002/hup.2394. Epub 2014 Mar 13.

PMID:
24911576
15.

Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.

Sun H, Yee KL, Gill S, Liu W, Li X, Panebianco D, Mangin E, Morrison D, McCrea J, Wagner JA, Troyer MD.

J Psychopharmacol. 2015 Nov;29(11):1159-69. doi: 10.1177/0269881115609015. Epub 2015 Oct 13. Erratum in: J Psychopharmacol. 2016 Jan;30(1):95.

PMID:
26464455
16.

Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.

Lowe SL, Wong CJ, Witcher J, Gonzales CR, Dickinson GL, Bell RL, Rorick-Kehn L, Weller M, Stoltz RR, Royalty J, Tauscher-Wisniewski S.

J Clin Pharmacol. 2014 Sep;54(9):968-78. doi: 10.1002/jcph.286. Epub 2014 Mar 26.

PMID:
24619932
17.

Subjective response to alcohol among alcohol-dependent individuals: effects of the μ-opioid receptor (OPRM1) gene and alcoholism severity.

Ray LA, Bujarski S, MacKillop J, Courtney KE, Monti PM, Miotto K.

Alcohol Clin Exp Res. 2013 Jan;37 Suppl 1:E116-24. doi: 10.1111/j.1530-0277.2012.01916.x. Epub 2012 Dec 14.

18.

Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.

Ray LA, Bujarski S, Squeglia LM, Ashenhurst JR, Anton RF.

Alcohol Alcohol. 2014 May-Jun;49(3):261-70. doi: 10.1093/alcalc/agt183. Epub 2014 Jan 13.

19.

Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures.

Peciña M, Love T, Stohler CS, Goldman D, Zubieta JK.

Neuropsychopharmacology. 2015 Mar;40(4):957-65. doi: 10.1038/npp.2014.272. Epub 2014 Oct 13.

20.

A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.

Ray LA, Hutchison KE.

Alcohol Clin Exp Res. 2004 Dec;28(12):1789-95.

PMID:
15608594

Supplemental Content

Support Center